Preparing for China · patient guide

Myeloproliferative neoplasm care in China: what to prepare

Preparing for myeloproliferative neoplasm care in China starts with a clear, current diagnosis and a usable record set: blood counts over time, bone marrow and genetic reports, and the medicines you actually take. The receiving haematology team decides whether your case is suitable for assessment in China and what further tests are needed. Your job before travel is to assemble records, state your main question, and confirm the plan in writing.

Go to the practical guidance ↓
AI illustration: A female doctor in a white coat consulting with a female patient in a blue shirt at a desk with a clipboard and notebook.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

Start with the diagnosis, not the destination

Myeloproliferative neoplasms are a group of chronic blood disorders, and the label covers conditions that behave differently and are managed differently. The World Health Organization classification and the International Consensus Classification both set out how these diseases are defined, and the two are not identical in every detail. That matters for an overseas enquiry: a vague label such as "MPN" or "myeloproliferative disorder" does not tell a haematologist which condition you have, what your risk category is, or what you are actually asking them to review.

Before approaching any hospital in China, find the document that states your specific diagnosis and the criteria used to reach it. If your records say only "suspected MPN" or "essential thrombocytosis versus reactive thrombocytosis", say so plainly. A receiving clinician needs to know whether the diagnosis is established or still being worked out, because those are different questions with different record needs.

You do not need to resolve the diagnosis yourself. You do need to avoid presenting an uncertain label as settled. If your local team has not confirmed the subtype, ask them what remains unresolved and include that question in your enquiry.

Related treatment reference

The records a haematology reviewer can actually use

Haematology review is record-heavy. A single recent blood count tells far less than a trend, and a bone marrow report without the accompanying genetic results may be incomplete for classification. Assemble records in a way that lets a clinician see the trajectory of your disease rather than a snapshot.

Blood counts over time are central. Ask your laboratory for a table or printout of full blood counts with dates, not just the most recent result. If your platelet or white cell counts have moved substantially, the dates of those changes matter. Include any documented thrombotic or bleeding events, because these affect how clinicians think about risk in these conditions.

Bone marrow aspirate and trephine biopsy reports should be included in full, with the reporting pathologist's conclusions. If a biopsy was done some time ago and never repeated, note the date. Genetic and molecular results are equally important: JAK2, CALR and MPL testing are part of how these conditions are classified, and other findings may have been reported alongside them. Send the actual reports, not a summary you have written from memory.

Medication records should list what you take now, the dose, and when you started or changed it. Include anticoagulants, cytoreductive therapy, interferon, hydroxycarbamide or any other agent your team has prescribed, plus relevant supportive medicines. Do not stop or alter any medicine in preparation for an enquiry; that is a decision for your prescribing clinician.

Finally, include a short list of your own questions. A reviewer who knows you are asking about diagnostic confirmation, treatment options, or a second opinion on monitoring will read the same records differently from one who is simply asked to "take a look".

  • Full blood count reports with dates, showing trends rather than one result
  • Bone marrow aspirate and biopsy reports, including the pathologist's conclusion
  • JAK2, CALR, MPL and any other molecular or cytogenetic reports
  • Current medicines with doses and start dates
  • A dated list of thrombotic, bleeding or other significant events
  • Your main question, written in one or two sentences

What a records-based review can and cannot settle

A remote review of your records can help clarify whether your diagnosis appears complete, whether the classification is consistent with the reported findings, and what a haematology team might want to examine or repeat. It can also help you decide whether travelling to China for assessment is worth pursuing at all.

It cannot establish hospital acceptance, confirm that a particular treatment will be available to you, or replace an in-person assessment. Haematology decisions often depend on examination findings, current blood counts taken at the treating centre, and sometimes on tests that must be done locally. A records-based opinion is a starting point for that conversation, not a substitute for it.

Be cautious about anyone who offers a definitive treatment plan before seeing you. For chronic blood conditions, management is usually a long-term strategy rather than a single procedure, and the appropriate approach depends on your subtype, risk profile, age, other conditions and prior treatment. Those are clinical judgements for the treating haematologist.

Questions to put to the treating team in China

The most useful preparation is a short, specific question list. Generic requests produce generic replies. Frame your questions around what you need to decide: whether to travel, what assessment would involve, and how care would continue afterwards.

Ask whether the team considers your diagnosis confirmed on the records provided, and if not, what they would need to establish it. Ask which tests they would expect to arrange during an assessment visit and whether any can be done before you travel. Ask how they would approach treatment if you were accepted, and what monitoring that would require.

For anyone considering care abroad with a chronic condition, continuity matters as much as the initial consultation. Ask how the team would communicate with your haematologist at home, what they would send back, and how ongoing monitoring would be handled if you return. These are practical questions, and a well-organised service should be able to tell you what is confirmed and what still depends on the hospital.

Ask, too, about the limits of what has been offered. If a reply describes a treatment as available, ask whether that means available to you after assessment or simply that the hospital uses it. The distinction is important and should be answered plainly.

Practical arrangements and what to confirm in writing

Once a haematology team has indicated that an assessment is reasonable, the practical questions become concrete. Which hospital department would see you, and is the consultation in a standard or international setting? What records must arrive before an appointment can be arranged? What language support is available during the consultation, and who provides it?

Costs need the same specificity. Hospital consultation, testing and treatment charges are set by the hospital, and our coordination fees are separate. We do not publish a standard fee for haematology treatment coordination, because the scope depends on the case. Ask for a written outline of what is included in any quote and what is billed separately by the hospital, rather than relying on a verbal estimate.

Travel planning should follow clinical advice, not precede it. Do not book flights on the assumption that an assessment will lead to treatment. Ask the treating team what they would need to see before advising on travel, and keep your arrangements changeable until the plan is confirmed.

If you use a coordination service, keep the clinical and non-clinical roles clear. Bilingual hospital navigation and interpretation are practical support, not clinical care, and the treating clinicians remain responsible for diagnosis and treatment decisions.

A realistic next step

Begin with a brief summary rather than a complete archive: your diagnosis or suspected diagnosis, the date it was established, your current treatment, and the one question you most want answered. Our team can check whether the available records and your main question are clear enough for a haematology enquiry, identify obvious gaps, and suggest the relevant next step. This initial review is free and is not a diagnosis or a promise of acceptance.

From there, you can decide whether a records-based specialist opinion or an appointment request is worth pursuing. Either way, the hospital and its haematologists decide suitability, and any treatment plan follows their assessment. Preparing well means giving them a clear picture and asking questions they can actually answer.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. myeloproliferative neoplasm care
  2. Related treatment reference
  3. Myeloproliferative Neoplasms Treatment - NCI

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.